Slingshot members are tracking this event:

Pfizer's (PFE) IBRANCE + Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer Recommended for Approval by European Ad Comm

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 16, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Hr+/her2- Metastatic Breast Cancer, Ibrance, Endocrine Therapy, Chmp, European Medicines Agency